价格

Senhwa Biosciences, Inc.

ACTIVE

10F, No. 225, Beixin Rd., Sec. 3, New Taipei City, New Taipei, 中国www.senhwabiosciences.comPublic

概览

试验阶段分布

阶段

试验数

占比

1 期

66.7%

2 期

33.3%

试验状态分布

已完成

66.7%

招募中

16.7%

终止

16.7%

药物批准

暂无批准数据

资讯

Silmitasertib Trial Launched for Childhood Solid Tumors

- A clinical trial is underway to assess silmitasertib combined with chemotherapy for treating solid tumors in children and young adults. - The trial aims to determine the recommended dose of silmitasertib and evaluate its safety, tolerability, and efficacy in cancer patients. - The study focuses on cancers like neuroblastoma, Ewing sarcoma, osteosarcoma, rhabdomyosarcoma, and liposarcoma, enrolling up to 114 participants. - Penn State College of Medicine, Beat Childhood Cancer Research Consortium, Four Diamonds, and Senhwa Biosciences are collaborating on this research effort.

Sep 30, 2024

返回机构列表

Senhwa Biosciences, Inc.

概览

试验阶段分布

试验状态分布

相关临床试验

该机构主办的试验（6）

CX-4945 in Viral Community Acquired Pneumonia

A Study of Silmitasertib (CX-4945) in Healthy Subject

Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation

Evaluating Safety, Pharmacokinetics and Clinical Benefit of Silmitasertib (CX-4945) in Subjects With Moderate COVID-19

Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC)

Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma

药物批准

资讯

Silmitasertib Trial Launched for Childhood Solid Tumors